Quadrant industry speaker series
The Quadrant Industry Speaker Series is designed to provide top level industry scientists an opportunity to visit UCSF, UC Berkeley, or UC Santa Cruz and present a public seminar to students, postdocs and the greater entrepreneurial community about the science that takes place within an established company. Many of the talks detail the optimization process that occurs while going from exciting science to a commercial product. We hope to host speakers throughout the healthcare continuum from the pharmaceutical, biotech, medical device and research tools industries. To keep posted on these events please sign up for our mailing list. Interested in speaking? Email Neena Kadaba.
All talks take place on the UCSF Mission Bay campus unless otherwise indicated. Lunch is provided, but space is limited, so please register to attend.
Ron Newbold, VP and Head, Strategic Research Partnerships within External R&D Innovation, Pfizer Worldwide Research and Development
“Innovating within Pharma: the role of strategic partnerships with academia”
Thursday, June 27, 2013
UCSF Mission Bay, Byers Hall, Room 212
Ron will describe the importance that Pfizer places on working with academic partners to advance early stage discovery. He will also discuss how Pfizer identifies and establishes these partnerships and in turn the best ways for academics to find ways to engage Pfizer.
Dr. Ron Newbold is Head, Strategic Research Partnerships within External R&D Innovation. Ron and his group support established Worldwide Research & Development alliances with numerous universities and biotechnology companies. The mission of the External R&D organization is to strengthen Pfizer’s access to cutting edge science at institutions in the US and Europe in alignment with the needs of Pfizer’s research units. Ron’s group also has responsibility for the activities of The Pfizer Incubator and for Pfizer’s global scouting activities.
Ron brings to Pfizer significant experience in external partnering in the life sciences field from his previous activities in large pharma as well as entrepreneurial start-up experience with three early-stage biotech companies. After receiving his PhD in organic chemistry from the University of Rochester and a postdoctoral fellowship with Nobel Laureate E.J. Corey at Harvard University, he joined Merck where he founded and led their Strategic Research Initiatives licensing team from 1996-2004. Ron earned an MBA from Columbia Business School in 2003.
Following 14 years with Merck, Ron led business development for Sentigen Biosciences (founded by 2004 Nobel Laureate Richard Axel of Columbia University); Celldex Therapeutics (a spin-out from Medarex); and Auspex Pharmaceuticals, where he served as chief business oOfficer, prior to joining Pfizer in 2010.